OnKure Therapeutics (NASDAQ:OKUR) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of OnKure Therapeutics (NASDAQ:OKUR) from a sell rating to a hold rating in a research report released on Saturday morning.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of OnKure Therapeutics in a research report on Monday, December 22nd. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $27.00.

OnKure Therapeutics Stock Up 3.2%

Shares of OKUR opened at $3.90 on Friday. OnKure Therapeutics has a 52 week low of $1.70 and a 52 week high of $5.28. The company has a market capitalization of $52.85 million, a price-to-earnings ratio of -0.88 and a beta of 0.45. The stock’s 50-day moving average price is $2.86 and its 200-day moving average price is $2.88.

OnKure Therapeutics (NASDAQ:OKUR) last posted its earnings results on Monday, March 9th. The company reported ($0.99) EPS for the quarter, topping the consensus estimate of ($1.15) by $0.16. As a group, equities analysts anticipate that OnKure Therapeutics will post -4.05 EPS for the current fiscal year.

Hedge Funds Weigh In On OnKure Therapeutics

Hedge funds have recently made changes to their positions in the company. XTX Topco Ltd purchased a new position in shares of OnKure Therapeutics in the fourth quarter valued at approximately $52,000. ADAR1 Capital Management LLC acquired a new stake in shares of OnKure Therapeutics in the fourth quarter worth approximately $2,941,000. Kotler Kevin purchased a new stake in shares of OnKure Therapeutics during the fourth quarter worth approximately $573,000. Barclays PLC increased its position in shares of OnKure Therapeutics by 4,286.8% during the fourth quarter. Barclays PLC now owns 27,242 shares of the company’s stock worth $79,000 after purchasing an additional 26,621 shares in the last quarter. Finally, Prosight Management LP raised its stake in OnKure Therapeutics by 204.9% in the 4th quarter. Prosight Management LP now owns 816,909 shares of the company’s stock valued at $2,369,000 after purchasing an additional 548,950 shares during the last quarter. Institutional investors and hedge funds own 90.98% of the company’s stock.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.